

Carbon Reduction Plan

Supplier name: Aventis Pharma Limited

Publication Date: May 2026

Commitment to achieving Net Zero

Aventis Pharma Limited is committed to achieving Net Zero emissions by 2045.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases (GHGs) that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

| | |
|--|---------------------------------|
| Baseline Year: 01/01//2019 – 31/12/2019 (Financial Year 2019) | |
| Additional Details relating to the Baseline Emissions calculations | |
| The baseline exercise was carried out for the first time for the year 2019. The baseline has been restated compared to the Carbon Reduction Plan published by Aventis Pharma Limited in 2025 for the year 2024. The restatement of the figures is due to a change in methodology in which the global parent company's (Sanofi's) carbon footprint is used to pro-rata for the UK using volumes of medicines that are purchased and sold. Despite using the global parent company data, this CRP reflects the footprint and commitments of Aventis Pharma Limited; the bidding entity, in the UK. In future years when the data collection improves, Aventis Pharma Limited will restate the baseline value if changes result from improvements in data or the methodology used. The carbon footprint also extends beyond the scope of the PPN 06/21 regulations as all relevant Scope 3 categories have been included. | |
| Baseline year emissions: | |
| EMISSIONS | TOTAL (tCO₂e) |
| Scope 1 | 4,567 |
| Scope 2 | 2,283 |
| Scope 3* | 50,234 |
| Total Emissions | 57,085 |

*Included sources for Scope 3 emissions are as follows: purchase of goods and services, capital goods, fuel and energy related activities (FERA), upstream transportation and distribution of goods, waste, business travel, employee commuting, downstream transportation and distribution of goods, processing of sold products, use of sold products, end-of-life treatment and investments.

Current Emissions Reporting


As per the baseline year, the below figures for 2025, 2024, and 2023 have been restated, in line with the change in methodology stated above.

| EMISSIONS | Reporting Year | | |
|--|---|--|--|
| | Current Year: 01/01/2025 – 31/12/2025 (Financial year 2025) | Previous Year: 01/01/2024 – 31/12/2024 (Financial Year 2024) | Previous Year: 01/01/2023 – 31/12/2023 (Financial Year 2023) |
| Scope 1 | 1614 | 2073 | 2592 |
| Scope 2 (Location- based) | 478 | 527 | 648 |
| Scope 3* | 23,646 | 26,546 | 29,160 |
| Total emissions | 25,739 | 29,146 | 32,400 |

*Included sources for Scope 3 emissions are as follows: purchase of goods and services, capital goods, fuel and energy related activities (FERA), upstream transportation and distribution of goods, waste, business travel, employee commuting, downstream transportation and distribution of goods, processing of sold products, use of sold products, end-of-life treatment and investments.

Emissions Reduction targets

Aventis Pharma Limited has set a target to achieve Net Zero by 2045. The graph below shows that when mapping the Net Zero trajectory required from the 2019 baseline, Aventis Pharma Limited are currently on track to meet Net Zero by 2045. Progress against our 2045 Net Zero commitment will be tracked annually, and the graph below will be updated.



Carbon Reduction Projects

At the parent company level, the following initiatives have been completed or actioned which also has a positive impact on the bidding entity:

- Our operational waste objective is to reduce our waste index by 30% by 2030 vs. 2019, which is a performance indicator that monitors our efforts on waste reduction and end-of-life environmental impact minimisation according to the waste treatment hierarchy.
- 0.8% landfill rate, 72% of our sites are landfill-free.
- 89.4 of our waste has been reused, recycled or recovered.
- 29% reduction in freshwater withdrawals (vs. 2019 baseline).
- Purchase 100% renewable energy across global operations by 2030. Currently, 86% of our energy is sourced from renewable electricity.
- Foster an eco-fleet (100% of fleet will contain fully electric vehicles) by 2030. Currently, 60% of the car fleet is an eco-fleet.
- Reduce GHG emissions from our activities (Scope 1&2) by 55% by the end of 2030. Currently, we stand at 49% GHG emissions reduction achieved (Scopes 1 & 2 vs. 2019).
- Reduce Scope 3 GHG emissions by 30% by the end of 2030. Currently, we stand at a 14% Scope 3 GHG emissions reduction achieved (vs.2019).
- Implementation of water efficiency plans with local targets on all sites by the end of 2020.
- Biodiversity management plans at priority sites by the end of 2025 and at all sites located near sensitive areas by the end of 2030.

- Potential impacts of all top-100 selling medicines have been assessed.
- 100% of our new medicines & vaccines follow an Eco-design approach. Applying Eco-design to all of our top-20 selling products by the end of 2030, with 50% of our top-20 already adopting Eco-design.

Aventis Pharma Limited have actioned or have completed the following carbon reduction projects since the baseline year of 2019 to support the reduction required to meet net zero by 2045:

- Procuring 100% renewable electricity at the UK Reading Head Office.
- All office, meeting rooms, communal area and LED car park lighting are controlled by PIR sensors and non-occupancy timers to minimise energy wastage in unoccupied areas.
- Transition of our car fleet towards carbon neutrality by 2030, and as part of this, the company car scheme aims to be fully electric in the next 2 years and for every electric car leased, our supplier plants a tree, and we have installed 30 additional Battery Electric Vehicle chargers onsite at Reading.
- Achieved ISO 14001 Environmental Certification in 2023 and again in 2025.
- Food waste is tracked in order to reduce wastage and to identify opportunities.
- We grow our own vegetables and herbs on our local rooftop, ensuring fresh organic produce within our restaurant.
- Reduced food deliveries and consolidated our deliveries into fewer weekly kitchen drop-offs by using a local supplier.
- Our kitchen is committed to only using red meat in 20% of our menus.
- If any trees need to be cut back or down due to disease, we chip the trees and use the chippings as mulch. The chippings rot down, then enrich the soil and help plants to grow.
- We have changed our Fruit supplier to "Fruitful Office", they will plant a fruit tree for every basket they deliver.
- Logistics suppliers are upgrading their facilities with increased site automation, implementing LED lighting, digitising customer invoices and increasing their use of electric vans in some areas.
- Bra recycling scheme to support against breast cancer, in which we have collected 8.3kg of bras.
- Sanofi's RePen pilot recycling initiative, which addresses the UK's 1,500-tonne annual insulin pen waste challenge by enabling patients to utilise a free postal return of used injectable pens. To date, 5,173 recycling envelopes have been ordered, with 2,346 envelopes returned, resulting in 28,198 pens recycled, helping reduce plastic waste and improve end-of-life product circularity.

Future Carbon Reduction Initiatives

- Global / UK Procurement-led initiatives are underway to partner with Sanofi Suppliers on Environment, Social and Governance (ESG) maturation and decarbonisation of our processes.
- We plan to decarbonise our supply chain by engaging with key suppliers and encourage them to decarbonise and set emissions reduction targets aligned with our own targets.
- Life Cycle Analysis of certain products in the UK to allow for eco-design and analysis of products for future waste reductions.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and the associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard and uses the appropriate Government emission conversion factors for greenhouse gas company reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.

This Carbon Reduction Plan has been reviewed and signed off on by the board of directors (or equivalent management body).

Signed on behalf of the supplier:



Ahmed Moussa

Date: 19.05.2026